Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT02251665
Active, not recruiting Observational

National Cerebral and Cardiovascular Center (NCVC) Stroke Registry

NCT02251665 · tracked via the Priya Life Science Japan tracker
Sponsor
National Cerebral and Cardiovascular Center, Japan
Phase
Observational
Started
2016-10
Last updated
2023-11-09

Condition(s) studied

Stroke, Acute

Investigational drug(s) / intervention(s)

No intervention

No intervention: a single-center prospective observational study

Study summary

A single-center registry of patients with acute ischemic stroke, intracerebral hemorrhage, and transient ischemic attack (TIA) who are emergently managed in the stroke care unit in the National Cerebral and Cardiovascular Center (NCVC) to determine change in underlying characteristics, stroke features and severity, process for diagnosis and acute treatment, and long-term outcomes of stroke/TIA patients over the years.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. A patient with acute ischemic stroke, intracerebral hemorrhage, and transient ischemic attack who are emergently managed in the stroke care unit or stroke units in the National Cerebral and Cardiovascular Center (NCVC) 2. Consent to participate in the registration by a patient or relatives obtained using an opt-out approach by the demonstrating contents of the registration on the hospital bulletin board Exclusion Criteria: 1\) Patients considered by the investigator to be unsuitable for participating in this registry

Primary outcome measure(s)

  • The modified Rankin Scale (mRS), a measure of disability — 3 monhts
    mRS scores range from 0 (no symptoms at all) to 6 (death)

Trial sites (1)

FacilityCityRegionStatus
National Cerebral and Cardiovascular Center Suita Osaka

More National Cerebral and Cardiovascular Center, Japan trials in Japan

Japanese Catheter Ablation Registry Recruiting
REASSURE-NIRS Registry Recruiting
Japanese Lead Extraction Registry Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02251665 on ClinicalTrials.gov ↗ ← All trials in Japan